Liminal BioSciences Stock Is Trading Higher On Sale Of Priority Review Voucher For $105M

by Vandana Singh, Benzinga Editor

August 9, 2021 11:52 AM | 1 min read |

Liminal BioSciences Inc's LMNL subsidiary Prometic Biotherapeutics Inc has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $105M.
The FDA granted the PRV with the approval of Ryplazim (plasminogen, human-tvmh) for plasminogen deficiency type 1 (hypoplasminogenemia).
Hypoplasminogenemia is characterized by a lack of a plasminogen protein, causing the development of growths (lesions) that can impair normal tissue and organ function.
Liminal Biosciences is entitled to retain an amount equal to 70% of the net sales proceeds of the sale of the PRV.
Jefferies LLC acted as exclusive financial advisor to Liminal BioSciences Inc. on this transaction.
Price Action: LMNL shares are up 29% at $3.69 during the market session on the last check Monday.

Posted In: Biotech Long Ideas News Penny Stocks Health Care Asset Sales Movers Trading Ideas General Briefs FDA Priority Review

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.